Ad hoc Announcement in Accordance with §15 WpHG Continuation of the SAPHIRE Study into the Second Recruitment Stage
News Jun 07, 2010
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, has announced the decision to advance the Phase II Hodgkin’s lymphoma (HL) SAPHIRE study with the HDAC inhibitor resminostat into the second Simon stage of patient recruitment.
This decision is based on the analysis of radiological imaging data from patients treated in the first Simon stage through an independent central assessment committee, which confirmed the achievement of the clinical activity requirements for the advancement of the trial.
4SC announced that the first patient had been treated in this trial on January 12, 2010. The Phase II SAPHIRE trial will continue into its second stage of patient recruitment and final results are expected, as planned, in the second half of 2011.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Clinical And Medical Microbiology
Sep 10 - Sep 11, 2018